Oncotarget · 2015 · 109 citations · 38 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaTumor ProgressionAngiogenesisAngiogenesis In CancerCancer Cell SignalingCancer ProgressionMyeloid-derived Suppressor CellsTumor PromotionAdenosine Receptor SignalingAdenosine-mediated SuppressionAngiogenesis In NeoplasmsAngiogenic Factor ExpressionMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell ModulationTumor Angiogenesis ModelsVascular Endothelial Growth Factor
// Claudia Sorrentino 1 , Lucio Miele 2 , Amalia Porta 1 , Aldo Pinto 1 , Silvana Morello 1 1 Department of Pharmacy, University of Salerno, Fisciano SA, Italy 2 Department of Genetics, School of Medicine, LSU Health Sciences Center, New Orleans, Louisiana, USA Correspondence to: Silvana Morello, e-mail: smorello@unisa.it Keywords: A2B adenosine receptor, myeloid-derived suppressor cells, tumor angiogenesis, melanoma Received: April 20, 2015 Accepted: June 15, 2015 Published: June 25, 2015 ABSTRACT Vascular endothelial growth factor (VEGF) is an angiogenic factor critically involved in tumor progression. Adenosine A2B receptor plays a pivotal role in promoting tumor growth. The aim of this study was to investigate the role of myeloid-derived suppressor cells (MDSCs) in the pro-angiogenic effects of A2B and to determine whether A2B blockade could enhance the effectiveness of anti-VEGF treatment. Mice treated with Bay60-6583, a selective A2B receptor agonist, showed enhanced tumor VEGF-A expression and vessel density. This effect was associated with accelerated tumor growth, which could be reversed with anti-VEGF treatment. Bay60-6583 increased the accumulation of tumor CD11b+Gr1+ cells. Depletion of MDSCs in mice significantly reduced A2B-induced VEGF production. However, A2B receptor stimulation did not directly regulate VEGF expression in isolated tumor myeloid cells. Mechanistically, Bay60-6583-treated melanoma tissues showed increased STAT3 activation. Inhibition of STAT3 significantly decreased the pro-tumor activity of Bay60-6583 and reduced tumor VEGF expression. Pharmacological blockade of A2B receptor with PSB1115 significantly reduced tumor growth by inhibiting tumor angiogenesis and increasing T cells numbers within the tumor microenvironment. These effects are, at least in part, dependent on impaired tumor accumulation of Gr1+ cells upon A2B receptor blockade. PSB1115 increased the effectiveness of anti-VEGF treatment.
38
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Guilian Niu, Kenneth L. Wright, Mei Huang et al. · Oncogene · 2002 · 1.2K citations